Tumor-specific MHC-II expression drives a unique pattern of resistance to immunotherapy via LAG-3/FCRL6 engagementDouglas B. Johnson, Justin M. Balko, Daniel Wang et al.|JCI Insight|2018Cited by 162
Prevalence and prognostic effect of high tumor mutation burden (TMB-H) across multiple less common solid cancers using a real-world datasetDaniel Backenroth, Wei Zhou, Changxia Shao et al.|Annals of Oncology|2019Cited by 2